ARGENX SE-ADR (NASDAQ:ARGX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday, October 31st. The brokerage presently has a $26.00 price objective on the stock. Zacks Investment Research‘s price target suggests a potential upside of 7.48% from the stock’s previous close.
According to Zacks, “argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. “
Separately, Cowen and Company reaffirmed a “buy” rating on shares of ARGENX SE-ADR in a report on Thursday, August 24th.
Shares of ARGENX SE-ADR (ARGX) traded down $0.15 during midday trading on Tuesday, reaching $24.19. 23,278 shares of the company’s stock were exchanged, compared to its average volume of 51,644. ARGENX SE-ADR has a 1 year low of $17.33 and a 1 year high of $27.25.
COPYRIGHT VIOLATION NOTICE: “ARGENX SE-ADR (ARGX) Upgraded by Zacks Investment Research to “Buy”” was first posted by BBNS and is the property of of BBNS. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/argenx-se-adr-argx-rating-increased-to-buy-at-zacks-investment-research/1746681.html.
A number of institutional investors have recently bought and sold shares of the business. Alyeska Investment Group L.P. grew its position in ARGENX SE-ADR by 1.8% in the third quarter. Alyeska Investment Group L.P. now owns 121,313 shares of the company’s stock worth $2,743,000 after buying an additional 2,167 shares during the last quarter. Nicholas Investment Partners LP acquired a new position in ARGENX SE-ADR in the 2nd quarter worth approximately $236,000. DAFNA Capital Management LLC acquired a new position in ARGENX SE-ADR in the 2nd quarter worth approximately $848,000. Artal Group S.A. acquired a new position in ARGENX SE-ADR in the 3rd quarter worth approximately $1,229,000. Finally, Tekla Capital Management LLC acquired a new position in ARGENX SE-ADR in the 2nd quarter worth approximately $1,591,000. Hedge funds and other institutional investors own 24.68% of the company’s stock.
ARGENX SE-ADR Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The companys lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ARGENX SE-ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARGENX SE-ADR and related companies with our FREE daily email newsletter.